Feasibility of new breast cancer genes as tumour markers for prognosis and management of breast cancer patients

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Project objective

Novel breast cancer genes essential for the development of sporadic breast malignancies have been identified by differential display and subtractive cDNA cloning strategies. The gene products of DIT1A12, an insulin-like growth factor binding protein, and T2E5, a human membrane protein, will be evaluated for their feasibility as tumour markers in breast cancer patient serum and biopsies. An Elisa method for larger scale screening of serum samples and an insitu hybridisation technique to examine gene expression in tissue specimen will be developed. If the genes are useful markers, they can be exploited for breast cancer detection kits. This joint venture of Canadian and British-German research teams will apply advances in molecular oncology in a disease oriented manner to give, if successful, oncologists a tool for early detection and prognosis of breast malignancies and subsequent women diagnosed with breast cancer or breast cancer predisposition increased chances for effective treatment and survival.

Original text from CORDIS.

Participants

• UNIVERSITY OF BRADFORD · BRADFORDCoordinatorUnited Kingdom
• Not availableCity levelGermany

Links

• View on CORDIS